Sonnet pivots into a $888 million Hyperliquid hype-centric ventureGrow AnalystJuly 17, 20250 Publicly available biotechnology company Sonnet Biotherapeutics has announced a decisive merger agreement with Rorschach I LLC, a newly formed entity…